Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Previously Treated Advanced NSCLC
NCT00787267Phase 2Terminated
- Sponsor
- Duke University
- Start
- Sep 2008
- Primary completion
- Jun 2013
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib in non-small cell lung cancer (NSCLC), sponsored by Duke University. Primary endpoint: Tumor Response at 2 years. Started Sep 2008; status: terminated.
02
Drugs
dasatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00787267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00787267.